Close Menu

Breaking News

The group aims to develop a transcriptomic and epigenetic biomarker assay for early detection and relapse monitoring in colorectal cancer patients. 

The test is designed to analyze the expression of 17 genes in order to differentiate mild and aggressive forms of Crohn's disease and ulcerative colitis.

AstraZeneca and Merck also announced they have filed for approval of Lynparza in patients who have mutations in more than a dozen homologous recombination repair genes.

Since 2017, the companies have been jointly developing an in vitro assay for measurement of sTREM-1 in plasma samples of septic shock patients. 

Eurofins LifeCodexx will commercialize Osteolabs' osteoporosis test in Germany, while BioGen Medical will do the same in Turkey.

An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.

The company reported performance changes that led to the product recall and said it is pursuing eventual FDA clearance for the devices.

The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.

The researchers will use Agilent's Fourier-transform infrared spectroscopy technology to monitor infants and determine those at highest risk of developing atopic eczema.

News items for the in vitro diagnostics industry for the week of Jan. 13, 2020.

The firm also has an early-access program for a new amplification strategy that combines 11 HLA genes for typing.

Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.

Ravitej Reddy pleaded guilty in federal court to allegations he illegally billed Medicare for cancer genomic testing and pharmacogenetic testing.

The financing round comes as Color expands its partnerships with healthcare systems and builds out a national genetic counseling resource for NIH's All of Us program.

CE marking of PromarkerD Hub complements the CE mark that the mass spectrometry version of the test received in November.

The FDA-cleared and CE-marked assay detects both fentanyl and norfentanyl, allowing labs to identify more true positives, according to Siemens.

The test adds to a menu of transplant monitoring assays that includes cytomegalovirus, Epstein-Barr virus, and BK virus.

Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.

Framingham, Massachusetts-based Kephera's tests is intended to be used to differentiate neurocysticercosis from other causes of seizures in patients.

The deal provides whole-genome sequencing for patients with rare diseases or cancer and could make sequencing part of the standard of care for NHS England.

The Nexus IB10 is a point-of-care platform that automatically separates plasma from whole blood for analyses with a range of different tests.

The guidance calls for communication to ensure doctors and patients understand what tests might be affected and to keep labs informed about patients' biotin intake.

Kindstar has also agreed to purchase Genesis systems for use by its scientists to monitor circulating tumor cells and for single-cell research.

The new test increases the multiplexing of the sepsis panel from 26 targets to 43 targets, including seven additional resistance genes.

GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.

Pages